Fucosylation improves hematopoietic stem cell homing and longevity, suggesting glycoengineering may enhance cancer therapy outcomes.
Fucosylation critically modulates E-selectin interactions, migration, and intracellular signaling in HSCs. These findings highlight glycoengineering as a promising strategy to enhance HSC transplantation outcomes in cancer therapy.
No takes yet. Share an insight, caveat, or question.
Al-Amoodi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: